Mekinist (trametinib tablets and oral solution – Novartis) — Cigna

Initial criteria

• Patient has BRAF V600 mutation-positive disease; AND
• The medication will be taken in combination with Tafinlar (dabrafenib capsules or tablets for oral suspension).

Approval duration

1 year